Introduction

Palmoplantar pustulosis, or pustulosis palmaris et plantaris (PPP), is a chronic, recurrent inflammatory skin disease that is sometimes unresponsive to conventional therapy. The anti-interleukin 23 antibody guselkumab is effective for treating PPP.

Areas covered

This review details the current understanding of PPP and discusses why guselkumab may be effective. Guselkumab is only approved for the treatment of PPP in Japan. In the United States, Canada, the European Union, and several other countries, it is approved for the treatment of moderate-to-severe plaque psoriasis, but not for PPP. Furthermore, guselkumab was approved only 1 year ago; its efficacy will be proven only by phase 2 and 3 clinical trials.

Expert opinion

The first double-blinded randomized placebo-controlled trial (RCT) of guselkumab for PPP has been completed. The drug was effective, and guselkumab could be used as a new agent for PPP treatment, in addition to several conventional therapeutics. However, several issues remain. For example, there is no mouse model of PPP, so careful observation of human PPP patients and establishment of a good experimental PPP model are essential.

中文翻译：

---

Guselkumab用于治疗掌plant脓疱病。

介绍

掌plant脓疱病或掌ust脓疱病（PPP）是一种慢性复发性发炎性皮肤病，有时对常规疗法无反应。抗白介素23抗体guselkumab可有效治疗PPP。

覆盖区域

这篇综述详细介绍了当前对PPP的理解，并讨论了为什么guselkumab可能有效。Guselkumab仅在日本被批准用于治疗PPP。在美国，加拿大，欧盟和其他几个国家，它被批准用于治疗中度至重度斑块状牛皮癣，但不适用于PPP。此外，guselkumab仅在1年前获得批准；仅在第2和第3期临床试验中才能证明其疗效。

专家意见

guselkumab用于PPP的首项双盲随机安慰剂对照试验（RCT）已完成。该药物是有效的，并且除了几种常规疗法外，古塞单抗还可以用作PPP治疗的新药。但是，仍然存在一些问题。例如，没有PPP的小鼠模型，因此仔细观察人类PPP患者和建立良好的实验性PPP模型至关重要。